USPTO Examiner CORNET JEAN P - Art Unit 1628

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19357447ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOFOctober 2025January 2026Allow300NoNo
19311344Selective Serotonin Receptor Modulators and Methods of Making and Using the SameAugust 2025January 2026Allow511YesNo
19096210METHODS FOR TREATING NEUTROPENIAMarch 2025June 2025Allow300NoNo
19029360METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASISJanuary 2025October 2025Allow911NoNo
19029592METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASISJanuary 2025November 2025Allow1011NoNo
19001859AGENT FOR INHIBITING RENAL DAMAGE INDUCED BY RHABDOMYOLYSISDecember 2024October 2025Abandon1010YesNo
18271036HYDROXYPENTYL BENZOIC ACID DIESTER COMPOUND, AND PREPARATION METHOD AND PHARMACEUTICAL APPLICATION THEREOFSeptember 2024June 2025Allow2401NoNo
18794778STABLE LIQUID COMPOSITIONS OF NETUPITANT AND PALONOSETRONAugust 2024March 2025Allow811YesNo
18629099METHODS OF TREATING ACUTE CORONARY SYNDROME USING 3,3'-DIINDOLYLMETHANEApril 2024September 2025Allow1811YesNo
18621624PRESBYOPIA TREATMENTSMarch 2024October 2025Abandon1911NoNo
18612665CHEMICALLY MODIFIED CURCUMINS FOR USE IN THE PRODUCTION OF LIPOXINSMarch 2024March 2026Abandon2321NoNo
18588730CAPSID INHIBITORS FOR THE TREATMENT OF HIVFebruary 2024February 2026Allow2420YesYes
18583643TETRACYCLINE COMPOSITIONSFebruary 2024August 2024Allow610YesNo
18444310READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATEFebruary 2024August 2024Allow610YesNo
18442061COMPOSITIONS AND METHODS FOR TREATING EPILEPSYFebruary 2024November 2024Allow911NoNo
18440388ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDSFebruary 2024February 2026Allow2421YesNo
18417252COMPOSITIONS AND METHODS FOR TREATING EPILEPSYJanuary 2024December 2024Allow1121NoNo
18413666ACID ADDITION SALTS OF BENZIMIDAZOLE DERIVATIVEJanuary 2024March 2025Allow1411NoNo
18405907COMBINATION COMPOSITIONJanuary 2024September 2024Allow910NoNo
18391876ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3December 2023March 2025Abandon1510NoNo
18393055TREATMENT OF AVASCULAR OR HYPOVASCULAR MICRO-TUMORSDecember 2023March 2025Abandon1510NoNo
18545754USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORINGDecember 2023February 2025Abandon1410NoNo
18532133METAL SALTS AND USES THEREOFDecember 2023November 2024Allow1110NoNo
18529497NOVEL WATER SOLUBLE NANO-SIZED IMINE RU(III) COMPLEX BASED ON 4-AMINOBENZENE SODIUM SULPHONATE FOR BIOMEDICAL APPLICATIONSDecember 2023March 2024Allow302YesNo
18516174PROCASPASE COMBINATION THERAPY FOR GLIOBLASTOMANovember 2023June 2025Allow1820YesNo
18381524METHODS FOR TREATMENT OF DISEASESOctober 2023September 2025Abandon2301NoNo
18487329FREEZE DRIED DRUG NANOSUSPENSIONSOctober 2023June 2025Abandon2001NoNo
18485799COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONISTOctober 2023December 2024Allow1510NoNo
18376308DISINFECTING COMPOSITION, APPLICATOR, AND METHOD OF DISINFECTINGOctober 2023August 2025Abandon2221NoNo
18450394APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASESAugust 2023June 2025Abandon2211NoNo
18232551PHYTOESTROGEN PRODUCT OF RED CLOVER AND PHARMACEUTICAL USES THEREOFAugust 2023November 2024Abandon1510NoNo
18364880USE OF A COMBINATION OF SACUBITRIL AND VALSARTANAugust 2023December 2024Abandon1610NoNo
18360752HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEFJuly 2023October 2024Allow1531NoNo
18225252COMPOSITIONS AND METHODS FOR TREATING EPILEPSYJuly 2023January 2024Allow602YesNo
18351682METHODS OF USING A PHENOXYPROPYLAMINE COMPOUND TO TREAT PAINJuly 2023October 2025Abandon2820NoYes
18217045METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT ON STATIN THERAPYJune 2023September 2024Abandon1410YesNo
18334690EPINEPHRINE SPRAY FORMULATIONSJune 2023July 2024Allow1320YesNo
18323435ANTIPLATELET DRUGS AND USES THEREOFMay 2023August 2023Allow300NoNo
18037102NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND ANTIBIOTIC COMPOSITION COMPRISING SAMEMay 2023February 2026Allow3311NoNo
18316911INJECTABLE SUSTAINED RELEASE BUPRENORPHINE FORMULATIONMay 2023May 2024Allow1240YesNo
18139349USE OF FENOLDOPAM FOR THE TREATMENT OF HEMOLYTIC UREMIC SYNDROMEApril 2023March 2025Abandon2320NoNo
18305303DOSAGE REGIMEN OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSIONApril 2023September 2024Allow1710NoNo
18247415AGENT FOR INHIBITING RENAL DAMAGE INDUCED BY RHABDOMYOLYSISMarch 2023May 2025Abandon2510NoNo
18187507OPHTHALMIC GEL COMPOSITIONS OF BIMATOPROST AND TIMOLOL AND ASSOCIATED METHODSMarch 2023May 2024Allow1430NoNo
18187471ENHANCED PENETRATION OPHTHALMIC COMPOSITIONS OF BIMATOPROST AND TIMOLOLMarch 2023February 2024Allow1120YesNo
18115286USES OF OXYGENATED CHOLESTEROL SULFATES (OCS)February 2023March 2026Abandon3710NoNo
18110879LIPOPHILIC ACTIVE ORAL FILM FORMULATION AND METHOD OF MAKING THE SAMEFebruary 2023December 2025Allow3421YesNo
18104970TREATMENT OF POST-OPERATIVE PAIN VIA SCIATIC NERVE BLOCK WITH SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONSFebruary 2023January 2024Allow1120NoNo
18018576ANTIPLATELET DRUGS AND USES THEREOFJanuary 2023April 2025Allow2611NoNo
18154550USE OF N-ACETYLCYSTEINE TO TREAT CENTRAL NERVOUS SYSTEM DISORDERSJanuary 2023February 2024Allow1320YesNo
18086141DICARBOXYLIC ACID BISAMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING DICARBOXYLIC ACID BISAMIDE DERIVATIVESDecember 2022September 2025Abandon3321YesNo
18069204STABLE LIQUID COMPOSITIONS OF NETUPITANT AND PALONOSETRONDecember 2022July 2024Allow1921NoNo
18065400COMBINATIONS OF BETA-LACTAM COMPOUNDS AND PROBENECID AND USES THEREOFDecember 2022July 2024Allow1910NoNo
18064587ABIRATERONE ACETATE CONTAINING COMPOSITION AND APPLICATION THEREOFDecember 2022July 2023Allow701NoNo
18061562PHARMACEUTICAL COMPOSITION FOR THE PARENTERAL ADMINISTRATION OF ULTRASHORT-EFFECTIVE BETA-ADRENORECEPTOR ANTAGONISTSDecember 2022April 2024Abandon1610NoNo
18059177TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASESNovember 2022April 2024Abandon1710NoNo
17927053N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTIONNovember 2022January 2026Abandon3801NoNo
17990806ACID ADDITION SALTS OF BENZIMIDAZOLE DERIVATIVENovember 2022October 2023Allow1000NoNo
18057116LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)November 2022May 2023Allow610YesNo
18054111METHODS FOR IMPROVED ENDOVASCULAR THROMBECTOMY USING 3,3'-DIINDOLYLMETHANENovember 2022January 2024Allow1421NoNo
17997393LERIGLITAZONE FOR TREATING LUNG INFLAMMATION AND INTERSTITIAL LUNG DISEASEOctober 2022December 2025Abandon3801NoNo
17922083APPLICATION OF HETEROCYCLIC COMPOUNDOctober 2022December 2025Abandon3801NoNo
17935839COMBINED TREATMENT REGIMEN OF ANESTHESIA/SEDATION WITH ADMINISTRATION OF PSYCHEDELIC DRUGS ASSOCIATED WITH REDUCTION IN NEUROPSYCHIATRIC ILLNESSSeptember 2022December 2025Abandon3901NoNo
17948842SUSTAINED RELEASE DEXAMETHASONE FORMULATIONSeptember 2022October 2025Abandon3730NoNo
17943708COMBINATION COMPOSITIONSeptember 2022October 2023Allow1300NoNo
17941509METHODS FOR TREATING NEUTROPENIASeptember 2022March 2025Allow3041YesNo
17821699METAL SALTS AND USES THEREOFAugust 2022September 2023Allow1200YesNo
17889029PANOBINOSTAT DOSAGES FOR MULTIPLE MYELOMAAugust 2022February 2024Abandon1810NoNo
17881874DOSING REGIMENS FOR 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDEAugust 2022August 2023Allow1200YesNo
17882458FORMULATIONS WITH ENHANCED SN-38 SOLUBILITY AND ORAL ABSORPTIONAugust 2022April 2025Allow3231YesNo
17877558METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASISJuly 2022September 2024Allow2530YesNo
17877564METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASISJuly 2022September 2024Allow2530YesNo
17870855INHIBITING DIHYDROFOLATE REDUCTASE IN A MICROORGANISMJuly 2022November 2025Abandon4001NoNo
17863250CARBONIC ACID ADDUCTSJuly 2022July 2025Allow3630NoNo
17811021MODULATORS OF TDP-43July 2022January 2024Abandon1821NoNo
17809733COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONSJune 2022August 2025Allow3721NoNo
17809745ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDSJune 2022November 2023Allow1610NoNo
17806575ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOFJune 2022March 2024Abandon2110NoNo
17784593THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTIONJune 2022November 2025Abandon4201NoNo
17783703TREATMENTS OF DIABETIC MACULAR EDEMA AND IMPAIRED VISUAL ACUITYJune 2022November 2025Abandon4110NoNo
17833293FREEZE DRIED DRUG NANOSUSPENSIONSJune 2022July 2023Allow1300NoNo
17779015PRODRUGS OF FULVESTRANTMay 2022January 2026Abandon4401NoNo
17734331ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3May 2022December 2023Abandon2010NoNo
17726305METHOD OF PROVIDING BIRTH CONTROLApril 2022December 2023Abandon2010NoNo
17720654NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTSApril 2022January 2026Allow4511YesNo
17719220Phosphonate-Drug ConjugatesApril 2022August 2025Allow4021NoNo
17765202TREATMENT OF ALCOHOLIC HEPATITISMarch 2022November 2025Abandon4310NoNo
17705443USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORINGMarch 2022December 2023Abandon2110NoNo
17697729INOSITOL PHOSPHATE COMPOUNDS FOR USE IN TREATING, INHIBITING THE PROGRESSION, OR PREVENTING CARDIOVASCULAR CALCIFICATIONMarch 2022January 2025Abandon3431NoNo
17642331TAK-925 FOR USE IN TREATING NARCOLEPSYMarch 2022September 2025Abandon4201NoNo
17753706ALVELESTAT FOR USE IN THE TREATMENT OF GRAFT REJECTION, BRONCHIOLITIS OBLITERANS SYNDROME AND GRAFT VERSUS HOST DISEASEMarch 2022February 2026Abandon4711NoNo
17688081BENZOQUINONE DERIVATIVE E3330 IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER AND ANGIOGENESISMarch 2022September 2024Abandon3130NoNo
17651042DIHYDRATE OF BENZOTHIOPHENE COMPOUND OR OF A SALT THEREOF, AND PROCESS FOR PRODUCING THE SAMEFebruary 2022November 2025Abandon4511NoNo
17670760ACEFAPC FOR THE TREATMENT OF ACETYLCHOLINE-DEPENDENT DISEASESFebruary 2022February 2024Abandon2401NoNo
17592244METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUSFebruary 2022March 2024Allow2510NoNo
17649780NASAL CANNABIDIOL COMPOSITIONSFebruary 2022May 2025Allow3930YesNo
17582485DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGHJanuary 2022July 2024Abandon3021NoNo
17582513COMPOSITIONS COMPRISING CAROTENOIDS AND USE THEREOFJanuary 2022December 2023Abandon2311NoNo
17627993Methods of treating sleep disorders associated with painJanuary 2022September 2025Abandon4401NoNo
17573777New Potent Antimicrobial Compounds with a Pyridazine NucleusJanuary 2022January 2023Allow1221YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CORNET, JEAN P.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
25
Examiner Affirmed
19
(76.0%)
Examiner Reversed
6
(24.0%)
Reversal Percentile
37.3%
Lower than average

What This Means

With a 24.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
167
Allowed After Appeal Filing
22
(13.2%)
Not Allowed After Appeal Filing
145
(86.8%)
Filing Benefit Percentile
16.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner CORNET, JEAN P - Prosecution Strategy Guide

Executive Summary

Examiner CORNET, JEAN P works in Art Unit 1628 and has examined 1,290 patent applications in our dataset. With an allowance rate of 41.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.

Allowance Patterns

Examiner CORNET, JEAN P's allowance rate of 41.3% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CORNET, JEAN P receive 2.23 office actions before reaching final disposition. This places the examiner in the 62% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CORNET, JEAN P is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +53.5% benefit to allowance rate for applications examined by CORNET, JEAN P. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.0% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 17.7% of cases where such amendments are filed. This entry rate is in the 20% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 38.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 71.6% of appeals filed. This is in the 60% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.8% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.1% of allowed cases (in the 75% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.1% of allowed cases (in the 62% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.